Decision analysis model comparing cost of multiparametric magnetic resonance imaging vs. repeat biopsy for detection of prostate cancer in men with prior negative findings on biopsy

Urologic Oncology: Seminars and Original Investigations

Volumn 33, Issue 6, 2015, Pages 266.e9-266.e16

  Lotan, Yair ^a   Haddad, Ahmed Q ^a   Costa, Daniel N ^a   Pedrosa, Ivan ^a   Rofsky, Neil M ^a   Roehrborn, Claus G ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Cost effectiveness; Magnetic resonance imaging; Prostate biopsy; Prostate cancer; Transrectal ultrasound

Indexed keywords

ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DECISION TREE; DIAGNOSTIC TEST ACCURACY STUDY; HEALTH CARE COST; HUMAN; HUMAN TISSUE; INCIDENCE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MEDICARE; MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; REIMBURSEMENT; REPEAT PROCEDURE; SENSITIVITY AND SPECIFICITY; TRANSRECTAL ULTRASONOGRAPHY; TUMOR BIOPSY; COST BENEFIT ANALYSIS; DEVICES; ECHOGRAPHY; ECONOMICS; IMAGE GUIDED BIOPSY; INTERVENTIONAL ULTRASONOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PROCEDURES; PROSTATE TUMOR; RADIOGRAPHY; RECTUM;

COST-BENEFIT ANALYSIS; HUMANS; IMAGE-GUIDED BIOPSY; MAGNETIC RESONANCE IMAGING; MALE; PROSTATIC NEOPLASMS; RECTUM; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 84929962754     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2015.03.007     Document Type: Article

References (42)

1. Siegel R., Desantis C., Jemal A. Colorectal cancer statistics, 2014. CA Cancer J Clin 2014, 64:104-117.
2. Mariotto A.B., Yabroff K.R., Shao Y., Feuer E.J., Brown M.L. Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst 2011, 103:117-128.
3. Heijnsdijk E.A., der Kinderen A., Wever E.M., Draisma G., Roobol M.J., de Koning H.J. Overdetection, overtreatment and costs in prostate-specific antigen screening for prostate cancer. Br J Cancer 2009, 101:1833-1838.
4. Carter H.B., Albertsen P.C., Barry M.J., et al. Early detection of prostate cancer: AUA guideline. J Urol 2013, 190:419-426.
5. Thompson I.M., Ankerst D.P., Chi C., et al. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0ng/ml or lower. J Am Med Assoc 2005, 294:66-70.
6. Adibi M., Pearle M.S., Lotan Y. Cost-effectiveness of standard vs intensive antibiotic regimens for transrectal ultrasonography (TRUS)-guided prostate biopsy prophylaxis. BJU Int 2012, 110:E86-E91.
7. Loeb S., Vellekoop A., Ahmed H.U., et al. Systematic review of complications of prostate biopsy. Eur Urol 2013, 64:876-892.
8. de Rooij M., Hamoen E.H., Futterer J.J., Barentsz J.O., Rovers M.M. Accuracy of multiparametric MRI for prostate cancer detection: a meta-analysis. Am J Roentgenol 2014, 202:343-351.
9. Mowatt G., Scotland G, Boachie C, et al. The diagnostic accuracy and cost-effectiveness of magnetic resonance spectroscopy and enhanced magnetic resonance imaging techniques in aiding the localisation of prostate abnormalities for biopsy: a systematic review and economic evaluation. Health Technol Assess 2013, 17:1-281.
10. Rastinehad A.R., Turkbey B., Salami SS, et al. Improving detection of clinically significant prostate cancer: magnetic resonance imaging/transrectal ultrasound fusion guided prostate biopsy. J Urol 2014, 191:1749-1754.
11. Siddiqui M.M., Rais-Bahrami S., Truong H., et al. Magnetic resonance imaging/ultrasound-fusion biopsy significantly upgrades prostate cancer versus systematic 12-core transrectal ultrasound biopsy. Eur Urol 2013, 64:713-719.
12. Vickers A.J., Sjoberg D.D., Ankerst D.P., Tangen C.M., Goodman P.J., Thompson I.M. The Prostate Cancer Prevention Trial risk calculator and the relationship between prostate-specific antigen and biopsy outcome. Cancer 2013, 119:3007-3011.
13. Wolters T., van der Kwast T.H., Vissers C.J., et al. False-negative prostate needle biopsies: frequency, histopathologic features, and follow-up. Am J Surg Pathol 2010, 34:35-43.
14. Rosario D.J., Lane J.A., Metcalfe C., et al. Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study. Br Med J 2012, 344:d7894.
15. Pokorny M.R., de Rooij M, Duncan E, et al. Prospective study of diagnostic accuracy comparing prostate cancer detection by transrectal ultrasound-guided biopsy versus magnetic resonance (MR) imaging with subsequent MR-guided biopsy in men without previous prostate biopsies. Eur Urol 2014, 66:22-29.
16. Loeb S., Carter H.B., Berndt S.I., Ricker W., Schaeffer E.M. Complications after prostate biopsy: data from SEER-Medicare. J Urol 2011, 186:1830-1834.
17. Gann P.H., Fought A., Deaton R., Catalona W.J., Vonesh E. Risk factors for prostate cancer detection after a negative biopsy: a novel multivariable longitudinal approach. J Clin Oncol 2010, 28:1714-1720.
18. Lopez-Corona E., Ohori M., Scardino P.T., Reuter V.E., Gonen M., Kattan M.W. A nomogram for predicting a positive repeat prostate biopsy in patients with a previous negative biopsy session. J Urol 2003, 170:1184-1188. [discussion: 1188].
19. Ploussard G., Nicolaiew N., Marchand C., et al. Risk of repeat biopsy and prostate cancer detection after an initial extended negative biopsy: longitudinal follow-up from a prospective trial. BJU Int 2013, 111:988-996.
20. Djavan B., Zlotta A., Remzi M., et al. Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1,051 men. J Urol 2000, 163:1144-1148. [discussion: 1148-1149].
21. Gosselaar C., Roobol M.J., Schroder F.H. Prevalence and characteristics of screen-detected prostate carcinomas at low prostate-specific antigen levels: aggressive or insignificant?. BJU Int 2005, 95:231-237.
22. Roehl K.A., Antenor J.A., Catalona W.J. Serial biopsy results in prostate cancer screening study. J Urol 2002, 167:2435-2439.
23. Aubry W., Lieberthal R., Willis A., Bagley G., Willis S.M., Layton A. Budget impact model: epigenetic assay can help avoid unnecessary repeated prostate biopsies and reduce healthcare spending. Am Health Drug Benefits 2013, 6:15-24.
24. Gittelman M.C., Hertzman B., Bailen J., et al. PCA3 molecular urine test as a predictor of repeat prostate biopsy outcome in men with previous negative biopsies: a prospective multicenter clinical study. J Urol 2013, 190:64-69.
25. Yanke B.V., Gonen M., Scardino P.T., Kattan M.W. Validation of a nomogram for predicting positive repeat biopsy for prostate cancer. J Urol 2005, 173:421-424.
26. Moore C.M., Robertson N.L., Arsanious N., et al. Image-guided prostate biopsy using magnetic resonance imaging-derived targets: a systematic review. Eur Urol 2013, 63:125-140.
27. Pinto P.A., Chung P.H., Rastinehad A.R., et al. Magnetic resonance imaging/ultrasound fusion guided prostate biopsy improves cancer detection following transrectal ultrasound biopsy and correlates with multiparametric magnetic resonance imaging. J Urol 2011, 186:1281-1285.
28. Costa D.N., Pedrosa I., Roehrborn C., Rofsky N.M. Multiparametric magnetic resonance imaging of the prostate: technical aspects and role in clinical management. Top Magn Reson Imaging 2014, 23:243-257.
29. Bjurlin M.A., Meng X., Le Nobin J., et al. Optimization of prostate biopsy: the role of magnetic resonance imaging targeted biopsy in detection, localization and risk assessment. J Urol 2014, 192:648-658.
30. Salami S.S., Ben-Levi E., Yaskiv O, et al. In patients with a previous negative prostate biopsy and a suspicious lesion on MRI, is a 12-core biopsy still necessary in addition to a targeted biopsy?. BJU Int 2015, 115(4):562-570.
31. Sonn G.A., Chang E., Natarajan S., et al. Value of targeted prostate biopsy using magnetic resonance-ultrasound fusion in men with prior negative biopsy and elevated prostate-specific antigen. Eur Urol 2014, 65:809-815.
32. Vourganti S., Rastinehad A., Yerram N.K., et al. Multiparametric magnetic resonance imaging and ultrasound fusion biopsy detect prostate cancer in patients with prior negative transrectal ultrasound biopsies. J Urol 2012, 188:2152-2157.
33. Hambrock T., Somford D.M., Hoeks C., et al. Magnetic resonance imaging guided prostate biopsy in men with repeat negative biopsies and increased prostate specific antigen. J Urol 2010, 183:520-527.
34. de Rooij M., Crienen S., Witjes J.A., Barentsz J.O., Rovers M.M., Grutters J.P. Cost-effectiveness of magnetic resonance (MR) imaging and MR-guided targeted biopsy versus systematic transrectal ultrasound-guided biopsy in diagnosing prostate cancer: a modelling study from a health care perspective. Eur Urol 2014, 66(3):430-436.
35. Hambrock T., Hoeks C., Hulsbergen-van de Kaa C, et al. Prospective assessment of prostate cancer aggressiveness using 3-T diffusion-weighted magnetic resonance imaging-guided biopsies versus a systematic 10-core transrectal ultrasound prostate biopsy cohort. Eur Urol 2012, 61:177-184.
36. Kim J.Y., Kim S.H., Kim Y.H., Lee H.J., Kim M.J., Choi M.S. Low-risk prostate cancer: the accuracy of multiparametric MR imaging for detection. Radiology 2014, 271:435-444.
37. Lawrence E.M., Tang S.Y., Barrett T., et al. Prostate cancer: performance characteristics of combined T(2)W and DW-MRI scoring in the setting of template transperineal re-biopsy using MR-TRUS fusion. Eur Radiol 2014, 24:1497-1505.
38. Puech P., Potiron E., Lemaitre L., et al. Dynamic contrast-enhanced-magnetic resonance imaging evaluation of intraprostatic prostate cancer: correlation with radical prostatectomy specimens. Urology 2009, 74:1094-1099.
39. Turkbey B., Shah V.P., Pang Y., et al. Is apparent diffusion coefficient associated with clinical risk scores for prostate cancers that are visible on 3-T MR images?. Radiology 2011, 258:488-495.
40. Wysock J.S., Rosenkrantz A.B., Huang W.C., et al. A prospective, blinded comparison of magnetic resonance (MR) imaging-ultrasound fusion and visual estimation in the performance of MR-targeted prostate biopsy: the PROFUS trial. Eur Urol 2014, 66:343-351.
41. Itatani R., Namimoto T., Atsuji S., et al. Negative predictive value of multiparametric MRI for prostate cancer detection: outcome of 5-year follow-up in men with negative findings on initial MRI studies. Eur J Radiol 2014, 83:1740-1745.
42. Lughezzani G., Lazzeri M., Haese A., et al. Multicenter European external validation of a prostate health index-based nomogram for predicting prostate cancer at extended biopsy. Eur Urol 2014, 66:906-912.